Publication of shareholders' letter

Paris (France), Copenhagen (Denmark)Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO), an innovative company specializing in the development of orphan oncology drugs, today announces the publication of its 8th Shareholders Letter.

This latest Shareholders Letter provides an update on Onxeo’s major achievements in 2015 with a focus on the positive results of the Phase I clinical trial of Bel-CHOP (association of belinostat with CHOP) and this quarters’ meetings between the Company and individual investors.

The Shareholders Letter is available on the company’s website at: (Media or Investors/Shareholders section).